Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials

Author： Tanizawa Yukio   Kaku Kohei   Araki Eiichi   Tobe Kazuyuki   Terauchi Yasuo   Utsunomiya Kazunori   Iwamoto Yasuhiko   Watada Hirotaka   Ohtsuka Wataru   Watanabe Daisuke   Suganami Hideki  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.15, Iss.6, 2014-04, pp. : 749-766

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

By Lamos Elizabeth M  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 6, 2013-06 ,pp. : 763-775

Informa Healthcare

Access to resources Recommend Favorite

Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes

By Boyle Luke D   Wilding John PH  

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 3, 2013-09 ,pp. : 375-391

Informa Healthcare

Access to resources Recommend Favorite

Comparative Efficacy of Vildagliptin and Sitagliptin in Japanese Patients with Type 2 Diabetes Mellitus: A Matching-Adjusted Indirect Comparison of Randomized Trials

By Signorovitch James E.  

Clinical Drug Investigation, Vol. 31, Iss. 9, 2011-09 ,pp. : 665-674

Adis International

Access to resources Recommend Favorite

Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus: Comparison with Other Oral Antihyperglycaemic Agents

By Derosa Giuseppe  

Drugs, Vol. 70, Iss. 15, 2010-10 ,pp. : 1945-1961

Adis International

Access to resources Recommend Favorite

Long-Term Safety and Tolerability of the Oral Direct Renin Inhibitor Aliskiren with Optional Add-On Hydrochlorothiazide in Patients with Hypertension: A Randomized, Open-Label, Parallel-Group, Multicentre, Dose-Escalation Study with an Extension Phase

By Sica Domenic  

Clinical Drug Investigation, Vol. 31, Iss. 12, 2011-12 ,pp. : 825-837

Adis International

Access to resources Recommend Favorite